Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
accepted:
12
01
2023
pubmed:
2
2
2023
medline:
17
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
The National Institute for Health and Care Excellence invited the manufacturer (Galapagos) of filgotinib (Jyseleca
Identifiants
pubmed: 36725788
doi: 10.1007/s40273-023-01244-z
pii: 10.1007/s40273-023-01244-z
pmc: PMC9929013
doi:
Substances chimiques
Adalimumab
FYS6T7F842
Biological Products
0
GLPG0634
0
Pyridines
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
239-251Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
National Institute for Health and Care Excellence. Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]. Committee papers. London: NICE; 2022. https://www.nice.org.uk/guidance/ta792/documents/committee-papers . Accessed 7 Nov 2022.
National Institute for Health and Care Excellence. Filgotinib for treating moderately to severely active ulcerative colitis. Technology appraisal guidance [TA792]. London: NICE; 2022. https://www.nice.org.uk/guidance/ta792/resources/filgotinib-for-treating-moderately-to-severely-active-ulcerative-colitis-pdf-82611613942981 . Accessed 7 Nov 2022.
National Institute for Health and Care Excellence. Filgotinib for treating moderate to severe rheumatoid arthritis: final scope. London: NICE; 2020. https://www.nice.org.uk/guidance/ta676/documents/final-scope . Accessed 1 Oct 2021.
Peyrin-Biroulet L, Dotan I, Hibi T, Taliadouros V, Oortwijn A, Zhao S, et al. OP25 Efficacy of filgotinib in patients with ulcerative colitis by line of therapy in the phase 2b/3 SELECTION trial J Crohns Colitis. 2021;15(Suppl._1):S024–6.
Gilead Sciences Inc. NCT02914535. Clinical study protocol: a long-term extension study to evaluate the safety of filgotinib in subjects with ulcerative colitis [PDF provided with the company’s submission]; 2019. p. 76. Accessed 17 Aug 2021.
National Institute for Health and Care Excellence. Vedolizumab for treating moderately to severely active ulcerative colitis. Technology appraisal guidance TA342. London: NICE; 2015. https://www.nice.org.uk/guidance/ta342 . Accessed 1 Nov 2021.
National Institute for Health and Care Excellence. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy. Technology appraisal guidance TA329. London: NICE; 2015. http://www.nice.org.uk/guidance/ta329 . Accessed 20 Aug 2021.
Ferrante M, Declerck S, De Hertogh G, Van Assche G, Geboes K, Rutgeerts P, et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2008;14(1):20–8.
doi: 10.1002/ibd.20278
pubmed: 17973304
Arseneau KO, Sultan S, Provenzale DT, Onken J, Bickston SJ, Foley E, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006;4(9):1135–42.
doi: 10.1016/j.cgh.2006.05.003
pubmed: 16829206
van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15.
doi: 10.1016/j.jval.2012.02.008
pubmed: 22867780
NHS. National cost collection 2019. London: NHS England and NHS improvement, 2020. https://www.england.nhs.uk/wp-content/uploads/2020/08/1_-_NCC_Report_FINAL_002.pdf . Accessed 19 Jan 2023.
Monthly Index of Medical Specialities (MIMS). 2021. http://www.mims.co.uk/ . Accessed 19 Jan 2023.
Einarson TR, Bereza BG, Ying Lee X, Lelli F. Dose escalation of biologics in Crohn’s disease: critical review of observational studies. Curr Med Res Opin. 2017;33(8):1433–49.
doi: 10.1080/03007995.2017.1335001
pubmed: 28537467
National Institute for Health and Care Excellence. Tofacitnib for moderately to severely active ulcerative colitis. Technology appraisal guidance TA547. London: NICE; 2018. https://www.nice.org.uk/guidance/ta547 . Accessed 1 Nov 2021.
Tsai HH, Punekar YS, Morris J, Fortun P. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008;28(10):1230–9.
doi: 10.1111/j.1365-2036.2008.03839.x
pubmed: 18729845
National Institute for Health and Care Excellence. Ustekinumab for treating moderately to severely active ulcerative colitis. Technology appraisal guidance TA633. London: NICE, 2020. https://www.nice.org.uk/guidance/ta633 . Accessed 1 Nov 2021.
National Institute for Health and Care Excellence. NICE Ppthways: ulcerative colitis overview. London: NICE; 2021 https://pathways.nice.org.uk/pathways/ulcerative-colitis . Accessed 17 Aug 2021.
Gemayel NC, Rizzello E, Atanasov P, Wirth D, Borsi A. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. Curr Med Res Opin. 2019;35(11):1911–23.
doi: 10.1080/03007995.2019.1631058
pubmed: 31192706